Integrated Symeres Offering Admescope's integration within the Symeres group enables cross-sell of ADME-Tox with integrated medicinal chemistry and discovery services, allowing you to present bundled packages to pharma and biotech clients seeking end-to-end preclinical optimization.

Biologics ADMET Growth Capitalize on the Biologics ADMET offering to target biologics and biosimilars programs needing tailored ADME-Tox evaluation, metabolite profiling, and binding/physicochemistry insights, expanding beyond small molecules.

US Market Focus Recent US-based business development hires signal a push into the US market. Prioritize outreach to US biotechs and pharma firms, positioning Admescope as a nimble, flexible partner for sponsor-driven ADME-Tox projects.

Discovery Edge Core ADME-Tox capabilities including in vitro metabolism, in vivo DMPK, drug interactions, and quantitative bioanalysis align with early discovery and lead optimization programs that require bespoke studies and actionable data.

Custom Solutions Admescope’s consultative, study-by-study approach and compound-specific optimization differentiate it from cookie-cutter CROs, enabling premium pricing and higher win rates for bespoke ADME-Tox strategies.